INmune Bio Inc (INMB)
11.64
+0.50
(+4.54%)
USD |
NASDAQ |
May 03, 16:00
11.64
0.00 (0.00%)
After-Hours: 20:00
INmune Bio Free Cash Flow (Quarterly): -3.401M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -3.401M |
September 30, 2023 | -4.264M |
June 30, 2023 | -3.174M |
March 31, 2023 | -1.141M |
December 31, 2022 | -5.695M |
September 30, 2022 | -3.367M |
June 30, 2022 | -4.759M |
March 31, 2022 | -8.865M |
December 31, 2021 | -9.78M |
September 30, 2021 | -7.923M |
June 30, 2021 | -20.71M |
March 31, 2021 | -5.092M |
Date | Value |
---|---|
December 31, 2020 | -2.392M |
September 30, 2020 | -3.698M |
June 30, 2020 | -1.818M |
March 31, 2020 | -1.035M |
December 31, 2019 | -0.4334M |
September 30, 2019 | -1.946M |
June 30, 2019 | -1.618M |
March 31, 2019 | -1.388M |
December 31, 2018 | -0.4624M |
September 30, 2018 | -0.4499M |
June 30, 2018 | -0.8178M |
March 31, 2018 | -0.3288M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-20.71M
Minimum
Jun 2021
-0.4334M
Maximum
Dec 2019
-4.795M
Average
-3.401M
Median
Dec 2023
Free Cash Flow (Quarterly) Benchmarks
Biomarin Pharmaceutical Inc | 12.87M |
Sarepta Therapeutics Inc | -284.52M |
Dare Bioscience Inc | -8.786M |
Zevra Therapeutics Inc | -16.23M |
Kodiak Sciences Inc | -59.72M |